Clinical Trial Update: A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF) [Phase 3]

View source ↗

Summary

Phase 3 trial results for Trikafta (elexacaftor/tezacaftor/ivacaftor) evaluating cough and physical activity in cystic fibrosis have been completed and results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Trikafta (elexacaftor/tezacaftor/ivacaftor) (elexacaftor/tezacaftor/ivacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2023-10-03